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m2 and oxaliplatin 130 mg/m2 on day 1, and S-1 40 mg/m2 twice a
day on days 1–14 of every 21-day cycle. This regimen seems to
have promising preliminary activity.
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P39 A20 BINDING AND INHIBITOR OF NF-KAPPAB (ABIN-1) – A
POTENTIAL MARKER FOR SURVIVAL IN EARLY STAGE NON-
SMALL-CELL LUNG CANCER AFTER LUNG RESECTION
L. Huang, C. Hu*, F. Li. Department of Internal Medicine, Xiangya
Hospital, Central South University, Changsha, Hunan, China
Background: Currently, the role of A20 binding and inhibitor of
NF-kappaB (ABIN-1) in the development of non-small-cell lung
cancer remains unknown. This retrospective study investigated
expression of ABIN-1 and the association with prognosis in
patients with NSCLC after lung resection.
Methods: Quantitative real-time reverse transcriptase (RT)-PCR,
and Western blot analyses were used to detect expression of ABIN-
1 in 30 samples of NSCLC tissue and paracarcinomatous lung tis-
sue (PCLT), and in four samples of normal lung tissue. In addition,
immunohistochemical analysis was done for 80 NSCLC speci-
mens, and follow-up data from these patients were reviewed.
Findings: Both mRNA and protein expression of ABIN-1 were
significantly raised in NSCLC tissues compared with normal lung
tissues. Patients with NSCLC who had high ABIN-1 expression
had shorter overall survival than patients who had low ABIN-1
expression.
Interpretation: The current data revealed that increased expres-
sion of ABIN-1 was correlated with survival in patients with
NSCLC, indicating that ABIN-1 is a novel prognostic marker for
NSCLC.
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Background: Transitional-cell carcinoma (TCC) of the urinary
bladder is reported as the eighth most common malignancy and
the fourth most common among men in Pakistan. This study
aimed to assess the clinicopathological pattern, p53 status, and
stage distribution of TCC, and to classify bladder carcinomas pre-
senting among the population of central Punjab, including factory
workers, according to the revised WHO/ISUP criteria.
Methods: 145 patients, including 52 factory workers (mean age
35.2 years), with newly diagnosed operable primary bladder car-
cinomas who underwent cystoscopy-associated transurethral
resection of bladder tumours from January, 2004, to July, 2006,
were included. Relevant clinical and laboratory data of these
patients, including age, sex, tumour location, and type of surgi-
cal procedure, were recorded in separate proformas. After confir-
mation of the diagnosis, the tumours were graded separately for
each group – first, according to WHO Classification 1972 as pap-
illoma, TCC grade I, II, and III, and later, according to WHO/ISUP
Consensus Classification 1998 as papilloma, papillary neoplasm
of low malignant potential (PNLMP), low-grade papillary carci-
noma (LGPC), and high-grade papillary carcinoma (HGPC).
Tumour staging was done according to TNM criteria of the
American Joint Commission on Cancer. All tissues were also
subjected to immunohistochemistry (IHC) with monoclonal
anti-P53 antibody. Patients were followed up for 3 years, from
hospital records until July, 2010. Data were entered and analysed
using SPSS 17.0.
Findings: About 80% of patients were men and 20% were
women (the male-to-female ratio was 5.3:1). Clinical history was
similar for both sexes, with most patients (74%) presenting with
haematuria with or without altered urinary habits. WHO grading
revealed 35.9% grade I, 25.4% grade II, and 38.6% of tumours as
grade III. ISUP classification revealed 19.2% PNULMP, 23.6% LGPC,
39.4% HGPC, 9.6% non-papillary urothelial carcinomas (NPUC),
and 7.9% as carcinoma in situ (CIS). Tumour staging depicted an
overall 11.5% of tumours with stage Ta and 31.5% with stage T3-
4. Among 71% invasive carcinomas, 16% were low-grade and
84% were high-grade carcinomas. Immunohistochemical staining
of histological tissue sections of 73% of CIS and 84.23% of TCCs
were p53 positive. 10.7% of grade I, 44.9% of grade II, and 92.1%
of grade III tumours were positive for p53. There were signifi-
cantly more p53-positive cases seen in grade II–III tumours than
in grade I tumours (p = 0.0036). Similarly, stage T2–T4 tumours
stained more frequently and stronger than stage T1 tumours
(p = 0.021). No significant association between p53 status and
post-operative prognosis was observed in the 3 years of follow-
up (p = 2.131).
Interpretation: Prolonged follow-up of patients with bladder
cancer may indicate an unfavourable prognostic factor linked to
histopathological findings, and the presence of p53 mutation,
which may also indicate development of aggressive growth char-
acteristics in TCCs.
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Background: We performed this retrospective study to assess
the association of mutations in the epidermal growth-factor
receptor (EGFR) gene with metastatic presentation in patients
with advanced non-small-cell lung cancer (NSCLC).
Methods: Data from 125 patients with stage III or IV NSCLC,
who were screened for EGFR mutations between March, 2007,
and June, 2010, were analysed.
Findings: We detected EGFR mutations in exons 18, 19, and 21
in 36 patients (29%). EGFR mutations were predominant in
never-smokers (p < 0.001), patients with adenocarcinoma
(p < 0.001), and female patients (p < 0.001). Analysis of metastatic
site with respect to mutation status showed that pleural metasta-
ses were associated with a high incidence of EGFR mutation
(p = 0.028) – particularly, pleural metastases with minimal effu-
sion (PMME; p = 0.001). Patients with N3 lesions were less likely
to harbour EGFR mutations (p = 0.033). In multivariate analysis,
N3 lesions (p = 0.017) and PMME (p < 0.001) remained significant
factors for EGFR mutations, whereas gender did not (p = 0.805).
Interpretation: Our data indicate that EGFR mutations may be
associated with different presentations of pleural and N3 nodal
metastases in patients with NSCLC.
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P42 BREAST-CANCER RISK FACTORS IN PAKISTANI WOMEN – A
CASE-CONTROL STUDY
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Background: There are limited data regarding risk factors for
breast cancer in Pakistan, although it is the most common
female cancer, with an incidence 2.5 times as high as other
countries in the region. This study investigated risk factors for
female breast cancer in a Pakistani population in southern
Punjab.
Methods: A case-control study was done in the fall of 2010,
involving 100 breast-cancer patients and 150 control individuals
who screened negative for breast cancer on mammography. Infor-
mation about demographic characteristics and potential risk fac-
tors for breast cancer was gathered from both groups using a
standard questionnaire. Logistic regression analysis was done to
determine the association of various potential risk factors with
breast cancer.
Findings: In multivariate logistic regression analysis, risk of
breast cancer was significantly increased in women older than 40
years (odds ratio [OR] 2.66, 95% CI 1.16–6.12), with more than four
full-term pregnancies (OR 5.33, 1.96–14.53), married (OR 2.35,
1.34–3.14), living in rural areas (OR 3.86, 1.63–9.13), and postmeno-
pausal (OR 4.19, 1.70–10.36). Breast-cancer risk was significantly
decreased in women with contraceptive use (OR 0.13, 0.02–1.04)
and no family history of breast cancer (OR 0.28, 0.12–0.69). In addi-
tion, no significant association was found between breast-cancer
risk and age at menarche, age at first live birth, age at menopause,
breastfeeding, and history of spontaneous or induced abortion.
Interpretation: The findings of this study suggest that age > 40
years, parity, marital status, locality, menopausal status, contra-
ceptive use, and family history of breast cancer are significantly
associated with breast-cancer risk in Pakistani women in south-
ern Punjab.
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Background: XELOX (combination therapy of capecitabine and
oxaliplatin) is known to cause nausea and vomiting, despite ade-
quate administration of antiemetics. Furthermore, specific risk
factors that may increase the risk of nausea and vomiting are
unknown.
Methods: This was a single-centre, prospective, cohort study.
Patients were recruited on the day of chemotherapy, and were fol-
lowed up after 5 days to assess nausea, vomiting, and use of
antiemetics. Patients were assessed for nausea and vomiting con-
trol, as well as complete response, complete protection, and com-
plete control of antiemetics. Use of delayed and breakthrough
antiemetics were assessed, and multivariable logistic regression
was done to evaluate risk factors that predisposed patients to
nausea and vomiting despite use of antiemetics.
Findings: 156 patients were included in this analysis. The med-
ian age was 60 years (IQR 55–65) with 88 (56.4%) men and 68
(43.6%) women. The proportion of patients achieving complete
response, complete protection, and complete control within 24
hours after chemotherapy was 87.8%, 80.8%, and 62.8%, respec-
tively. These proportions continued to decline throughout the fol-
low-up period to 76.9%, 64.7%, and 48.7%, respectively, at the end
of the 5 days. Patients who had fewer than three risk factors (odds
ratio [OR] 3.13, p = 0.006), who received oxaliplatin less than
100 mg/m2 (OR 3.23, p = 0.009), and who received capecitabine less
than 1500 mg/m2 (OR 5.00, p = 0.04) were more likely to achieve
complete response to antiemetics.
Interpretation: This study showed that an unacceptably high
proportion of patients receiving XELOX were unable to attain
adequate control of nausea. Future research should focus on
the optimisation of antiemetic therapy for patients receiving
XELOX.
Funding: National University of Singapore, Faculty of Science
start-up grant.
The authors declared no conflicts of interest.
doi:10.1016/j.ejcsup.2011.02.044
E J C SUP P L EMENTS 9 ( 2 0 1 1 ) 1 –2 3 17
